BAGSVAERD, Denmark I4, 2025 I Novo Nordisk today announced topline results from a phase 1b/2a clinical trial with amycretin, a unimolecular GLP-1 ...

EXUMA now advancing its clinically de-risked solid tumor & hematologic CARs with in vivo GCAR ™ platform and SCL mRNA technology WEST PALM BEACH, FL, USA I3, 2025 I EXUMA Biotech, Corp., a ...

The U.S. Food and Drug Administration (FDA) has granted andecaliximab a Rare Pediatric Disease Designation (RPDD) for the treatment of FOP. An RPDD designation is granted to potential treatments for ...

CAMBRIDGE, MA, USA & BRISBANE, Australia I2, 2025 I Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density ...

Trial aims to establish safety and provide proof of concept for GYS1 inhibition as promising new treatment strategy in patients with late-onset Pompe disease ...

DURHAM, NC, USA I2, 2025 I IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human ...

NORTH CHICAGO, IL and SAN DIEGO, CA, USA I3, 2025 I AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and ...

Novel breakthrough: first molecule to modulate the fundamental mechanism of T cell activation underlying autoimmune pathology ...

GAITHERSBURG, MD, USA I2, 2025 I Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing novel complex biologic therapeutics, today ...

About Cullgen Inc. Cullgen is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class new chemical entities (NCEs) for the treatment of diseases lacking effective ...

SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination ...

NEWTOWN SQUARE, PA, USA and SHANGHAI, China I1, 2025 I ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company ...